Skip to main content
. Author manuscript; available in PMC: 2015 Feb 4.
Published in final edited form as: Cancer Prev Res (Phila). 2014 Dec 23;8(2):157–164. doi: 10.1158/1940-6207.CAPR-14-0198

Table 3.

Test set results combined FOXE1 and SYNE1

SYNE1 and FOXE1

Patient group Positive Sensitivity
Stage I 10/27 37%
Stage II 13/15 87%
Stage III 11/20 55%
Stage IV 4/4 100%
Case total 38/66 58%
Specificity
Control 21/240 91%